VHL Syndrome with Diabetes Mellitus, and Pulmonary and Thyroid Nodules: A Case Report [0.03%]
VHL综合征合并糖尿病及肺、甲状腺结节病例报告
Zhiyuan Peng,Chuan Hua,Wenze Liu et al.
Zhiyuan Peng et al.
Von Hippel-Lindau (VHL) syndrome is an autosomal dominant hereditary tumor syndrome caused by mutations in the VHL gene. It is characterized by the occurrence of tumors in multiple organs. Pancreatic involvement in VHL syndrome can present ...
Partial Nephrectomy as Management of Oligometastatic Cancer with Limited Systemic Treatment Options: A Case Report [0.03%]
寡转移癌有限系统治疗选择下部分肾切除术的治疗案例报告
Chibuzor Victor Nwachukwu,Christopher Michael Brede,Gerald Paul Wright et al.
Chibuzor Victor Nwachukwu et al.
Ocular melanoma is a form of melanoma that rarely offers actionable mutations for treatment with systemic therapy and is relatively radioresistant. As such, surgery is the mainstay of treatment for localized disease and can be considered fo...
Long-term Safety and Efficacy of Belzutifan in Von Hippel-Lindau Syndrome: A VHL Coordinating Care Center Experience [0.03%]
Belzutifan治疗Von Hippel-Lindau病的长期安全性和有效性：VHL协调诊疗中心的经验报告
Paulo Siqueira do Amaral,Ricardo Borges Fonseca,Breanne Reisen et al.
Paulo Siqueira do Amaral et al.
Von Hippel-Lindau (VHL) disease is a rare inherited syndrome characterized by benign and malignant neoplasms. Belzutifan, a HIF-2α inhibitor, was approved for the treatment of VHL-associated neoplasms. As a first-in-class agent, understand...
Narrative Review of Von Hippel-Lindau Syndrome: From Discovery to Modern Medical and Surgical Therapies [0.03%]
Von Hippel-Lindau综合征的叙述性回顾：从发现到现代医疗和外科治疗
Danilo Coco,Silvana Leanza
Danilo Coco
The von Hippel-Lindau (VHL) syndrome is a rare autosomal dominant disorder caused by mutations in the VHL tumor suppressor gene, leading to the development of benign and malignant tumors in multiple organs, including the kidneys, brain, spi...
Ratika Dogra,Ulka Vaishampayan
Ratika Dogra
Hypoxia creates a stressful environment for the cells triggering adaptive changes in the transcription factors called hypoxia inducible factors (HIF), which help to meet the metabolic and angiogenic requirements of cells. HIF-2 is one such ...
Ulka Vaishampayan
Ulka Vaishampayan
Cabozantinib-Exposed Renal Cell Carcinoma Organoids Suggest Transcriptomic Associations with Treatment Resistance in Clear Cell and Nonclear Cell Tumors [0.03%]
卡博替尼暴露肾细胞癌类器官提示透明细胞和非透明细胞肿瘤的治疗抵抗与转录组学之间的联系
Wesley H Chou,Nicholas H Chakiryan,George V Thomas
Wesley H Chou
While vascular endothelial growth factor tyrosine kinase inhibitors (VEGF-TKIs) are a mainstay of treatment for advanced renal cell carcinoma (RCC), mechanisms of resistance to VEGF-TKIs remain under ongoing investigation. To assess transcr...
First-Line Ipilimumab with Nivolumab versus Immune Checkpoint Inhibitors with Tyrosine Kinase Inhibitors in Patients with Intermediate- or Poor-Risk Metastatic Clear Cell Renal Cell Carcinoma [0.03%]
一线伊匹木单抗联合尼伏木单抗与免疫检查点抑制剂联合酪氨酸激酶抑制剂治疗中危或高危转移性透明细胞肾细胞癌患者的对比研究
Micah Ostrowski,Yeonjung Jo,Georges Gebrael et al.
Micah Ostrowski et al.
Ipilimumab with nivolumab (Ipi + Nivo) and immune checkpoint inhibitors with tyrosine kinase inhibitors (ICI + TKI) are the first-line approved treatments for intermediate- and poor-risk metastatic clear cell renal cell carcinoma (mccRCC); ...
A Decade of Surgical Management of Renal Cell Carcinoma with IVC Thrombus and Bilateral Renal Tumors: Emphasis on Auto-transplantation [0.03%]
单中心十年来肾癌合并下腔静脉瘤栓及双侧肾肿瘤的外科治疗：自体移植为重点
Abdul Rouf Khwaja,Aamir Mushtaq,Younis Mushtaq et al.
Abdul Rouf Khwaja et al.
To assess the surgical outcomes and techniques in managing renal cell carcinoma (RCC) with inferior vena cava (IVC) thrombus and bilateral renal tumors with a focus on the role of autotransplantation in complex cases, this retrospective stu...
Reno-Gonadal Venous Anastomosis for Right Renal Venous Drainage Following Juxtarenal Cavectomy for Renal Cell Carcinoma [0.03%]
肾细胞癌伴肾下腔静脉切除后的右侧肾静脉回流重建术(Reno- gonadal静脉吻合)
Jabrina Simmons,Tae-Hee Kim,Tasha Posid et al.
Jabrina Simmons et al.
This article is a case report of a 62-year-old male with a left-sided renal cell carcinoma (RCC) with a level II inferior vena cava (IVC) thrombus and caval occlusion. He was managed with open left radical nephrectomy and juxtarenal cavecto...